GlassScriptPhysician profile
Arshad Aziz
NPI 1407221286
$4,372.28
in general payments reported to CMS, 2019-2025
30 companies · $883 in 2025
The $883 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $591 · 2023: $1,026 · 2024: $1,873 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,781.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.61 | 2022-2025 | |
| Eisai INC. | $417.66 | 2022-2025 | |
| Ucb, INC. | $374.63 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Amneal Pharmaceuticals LLC | $294.73 | 2022-2025 | Rytary, Crexont |
| Pfizer INC. | $253.94 | 2023-2025 | |
| Argenx US, INC. | $243.29 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $226.26 | 2022-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $226.00 | 2022-2025 | Reyvow, Emgality, Kisunla |
| Alexion Pharmaceuticals, INC. | $204.29 | 2023-2025 | Ultomiris, Koselugo |
| Novartis Pharmaceuticals Corporation | $186.89 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $171.80 | 2022-2024 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $142.61 | 2023-2024 | |
| Biogen, INC. | $115.50 | 2022-2023 | Vumerity |
| Neurelis, INC. | $90.30 | 2024-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $72.93 | 2025 | Nuplazid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $71.88 | 2024 | Hizentra |
| Emd Serono, INC. | $60.63 | 2022-2024 | Mavenclad |
| Sumitomo Pharma America, INC. | $59.59 | 2023-2024 | Aptiom |
| Corium, LLC | $59.01 | 2022-2023 | Adlarity |
| Acorda Therapeutics, INC | $58.12 | 2022-2023 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $48.25 | 2022 | |
| Merz Pharmaceuticals, LLC | $44.38 | 2024 | Xeomin |
| Otsuka America Pharmaceutical, INC. | $40.45 | 2024 | Rexulti |
| Lundbeck LLC | $39.21 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $30.61 | 2023 | Horizant |
| Ge Healthcare | $29.77 | 2023 | |
| Globus Medical, INC. | $22.68 | 2025 | Senza |
| Janssen Pharmaceuticals, INC | $21.31 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.24 | 2024 | Dojolvi |
| Impel Pharmaceuticals INC. | $14.71 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.